What happened in China’s first successful pediatric dual fully implantable artificial-heart case at Tianjin Taida International Cardiovascular Hospital—including the patient’s restrictive cardiomyopathy, simultaneous left- and right-heart failure, staged artificial-heart implanta

China’s Tianjin Taida International Cardiovascular Hospital reported a successful “dual artificial heart → heart transplant” rescue of a 5-year-old, 12.2-kg girl with restrictive cardiomyopathy and failure of both ventricles. It was presented as China’s first successful pediatric case using two fully implantable pumps and the lowest-body-weight successful case of its kind globally. 36

• Clinical course: The child’s restrictive cardiomyopathy had progressed to simultaneous left- and right-heart failure. The team used staged treatment: implanting two miniature, fully implantable ventricular-assist pumps as a bridge, then performing a donor-heart transplant; the two major operations occurred within 110 days. She reportedly recovered and was discharged. 36

• Why it was notable: At only 12.2 kg, she set the reported low-weight record for this type of successful dual-pump-plus-transplant treatment. The two pumps operated together for more than 40 days, maintaining circulation until an appropriately matched donor heart became available. 310

• Comparison with Berlin Heart EXCOR: EXCOR had been the key international long-term bridge-to-transplant option for infants and small children because it comes in pediatric pump sizes. But it is a paracorporeal, pneumatically driven system—pumps and driving equipment remain outside the body—rather than a fully implantable continuous-flow system. Published experience also identifies bleeding, thrombosis, infection, and device-management burdens as important limitations, especially in the smallest patients. 1356

• The engineering adaptation: Aerospace Taixin and the hospital adapted “Rocket Heart” technology derived from aerospace magnetic-levitation work. The reported design uses opposing motors and a three-dimensional magnetic-field arrangement to keep the rotor stably levitated without conventional active magnetic-bearing feedback hardware. 712

• Miniaturization: In an expedited pediatric redesign, each pump was reduced to 69 g. The sewing ring’s outside diameter was reduced from 29 mm to 22.4 mm, while its weight fell from 6.4 g to 1.17 g—changes intended to make implantation possible in the child’s very small thoracic cavity and heart. 1011

• Right-heart support: The team’s dedicated right-side pump addressed a major unmet need: most implantable VAD development has focused on left-heart support, while reliable dedicated right-heart support has remained scarce. In this case, simultaneous bilateral support was necessary because supporting only the left side would not resolve the child’s right-sided failure; it created the physiological stability and time needed for donor matching. 1016

• What it says about China’s sector: The case suggests that China is moving beyond adult left-VAD deployment toward specialized, small-body-size and biventricular support. Reporting at the time said five Chinese firms held six approved VAD products, while the regulator had previously described Core Medical’s 2023 device as the fourth domestically approved implantable LVAD. 137 The aerospace lineage is significant: earlier HeartCon work explicitly drew on Chinese rocket-system magnetic and fluid-levitation technology, demonstrating technology transfer from the China Academy of Launch Vehicle Technology ecosystem into implantable medical devices. 16

A caution: the “world first,” “world’s lightest,” and “global gap” descriptions are principally claims from hospital, government-development-zone, and company-linked reporting rather than a peer-reviewed comparative registry. The clinical result is compelling, but durable safety and broader reproducibility will require larger, independently reported pediatric series.